Abstract
AbstractThe injection of slow release antiglaucoma drugs could be an alternative in order to guarantee the adherence to glaucoma medical treatment and to reduce the rate of progression.There are multiple possibilities. In this moments, only slow release bimatoprost injection in anterior chamber has been approved by FDA. The hypotensive effect could be maintained for 6 months. Similar studies with sustained release of another prostaglandine analogs, like latanoprost and travoprost, are undergoing.Another option is the iDose containing travoprost that is implanted in the trabecular meshwork. A phase III study is undergone.Another possibility under investigation is supraciliary, subconjunctival, intravitreous and intrascleral injection of different active products.In the next future, the injection of antiglaucoma drugs could have an important role in glaucoma medical treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
